Next week at the inaugural GLP-1-Based Therapeutics Summit, Lars Johansson (Chief Scientific Officer @ Antaros Medical), will be discussing the insights that imaging can provide throughout the development of incretin-based therapies to better understand underlying mechanisms, assess body composition and weight loss, and investigate both systemic and organ-specific effects.
Incretin-based therapies, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have changed the treatment landscape in type 2 diabetes (T2D), obesity, and other metabolic diseases. With further opportunities for combinations of incretins (dual and triple agonists), as well as with other modes of action, and expansion into new disease indications, the growing trend regarding the number of incretin-based therapies in development is likely to continue.
But there is still a lot we don’t know about incretins, including GLP-1, and tools such as advanced imaging methods are needed to help understand the underlying mechanisms of incretin-based pharmacological interventions. Imaging-based measurements of body and muscle composition can also be used to comprehensively assess weight loss and its complexity. Advanced imaging methods can also be used to investigate systemic and organ-specific effects simultaneously.
To hear more, join us at the GLP-1-Based Therapeutics Summit on Wednesday 15 May @ 12:00 EDT to hear Lars’ talk ‘The Incretin Impact – how can imaging elucidate the effects of incretin-based therapies to support drug development’. The GLP-1-Based Therapeutics Summit takes place from 15-16 May in Philadelphia, PA.
To learn more about incretin-based drug development, you can also check out our latest webinar – ‘The Incretin Impact: A new era in metabolic disease and obesity drug development’.